Key result
Exposure therapy significantly decreased resting heart rate (B = -5.06, p = .024) and heart rate reactivity (B = -2.46, p = .005) from baseline to posttreatment relative to waitlist control.
Why the study?
Posttraumatic stress disorder is linked to cardiovascular disease, but relatively little is known about whether frontline PTSD treatments can alleviate cardiovascular risk.
Does exposure therapy reduce resting heart rate and heart rate reactivity in active-duty soldiers with PTSD?
RCT (n=104)
Does exposure therapy reduce resting heart rate and heart rate reactivity in active-duty soldiers with PTSD?
Effect estimate: B = -5.06 (resting HR), B = -2.46 (HR reactivity)
p-value: p=0.024 (resting HR), 0.005 (HR reactivity)
Exposure therapy for PTSD significantly reduces resting heart rate and heart rate reactivity compared to a waitlist control, suggesting a potential reduction in associated cardiovascular risk.
Supports exposure therapy to mitigate CV risk in PTSD; extends RCT evidence linking trauma-focused treatment to improved autonomic markers.
OBJECTIVE: Posttraumatic stress disorder (PTSD) is linked to poor health, including cardiovascular disease. These effects may be a result of increased tonic cardiovascular function and cardiovascular reactivity. Despite PTSD's negative health burden, relatively little is known about whether frontline treatments for PTSD may alleviate cardiovascular risk. METHODS: The current study was a secondary analysis of a larger intervention study of active-duty soldiers with PTSD (n = 104; mean [SD] age = 30.6 [6.7] years; 6% women) randomized to an exposure therapy-either prolonged exposure (PE) or virtual reality exposure (VRE)-or a waitlist control condition. We examined change in participants' resting heart rate (HR) and HR reactivity from baseline (before randomization) to midtreatment and posttreatment using residualized change regression models. RESULTS: The results of the study demonstrated decreased resting HR (B = -5.06, p = .024) and HR reactivity (B = -2.46, p = .005) from baseline to posttreatment of PE and VRE relative to waitlist. Exploratory analyses found that changes in resting HR and HR reactivity were not significantly correlated with either self-reported or clinician-rated PTSD symptom change. CONCLUSIONS: These results suggest that PE and VRE for PTSD may alleviate some cardiovascular health risk associated with PTSD, improving cardiovascular functioning.RCT Registration: ClinicalTrials.gov (identifier: NCT01193725).
No takes yet. Share an insight, caveat, or question.
Bourassa et al. (2019) conducted an RCT in Posttraumatic stress disorder (PTSD) (n=104). Exposure therapy (prolonged exposure or virtual reality exposure) vs. Waitlist control was evaluated on Change in resting heart rate (HR) and HR reactivity from baseline to posttreatment (B = -5.06 (resting HR), B = -2.46 (HR reactivity), p=0.024 (resting HR), 0.005 (HR reactivity)). Exposure therapy significantly decreased resting heart rate (B = -5.06, p = .024) and heart rate reactivity (B = -2.46, p = .005) from baseline to posttreatment relative to waitlist control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: